Skip to main content
S.C.P.C logo

S.C.P.C — Investor Relations & Filings

Ticker · 1720 ISIN · TW0001720001 TW Manufacturing
Open in API
Filings indexed 1,621 across all filing types
Latest filing 2022-08-02 Board/Management Inform…
Country TW Taiwan
Listing TW 1720

About S.C.P.C

http://www.standard.com.tw

Standard Chemical & Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical manufacturer established in 1967. The company specializes in the research, development, production, and marketing of a wide range of pharmaceutical products, including generic Western medicines, Active Pharmaceutical Ingredients (APIs), and healthcare supplements. Its therapeutic portfolio covers diverse areas such as cardiovascular, metabolic, respiratory, anti-infective, and musculoskeletal systems, as well as dermatological and urogenital treatments. As a prominent generic drug manufacturer, the company operates with an integrated business model that spans from high-tech R&D to brand management and distribution. Adhering to international quality standards and ISO 9001 certification, it focuses on technological innovation and sustainable growth to serve diverse healthcare needs across domestic and international markets.

Recent filings

Filing Released Lang Actions
公告本公司董事會通過解除經理人競業禁止案
Board/Management Information Classification · 95% confidence The document is a short announcement (819 characters) from a company (1720 生達) regarding a board resolution to approve the removal of a non-compete restriction for a manager. It details the decision date, the manager's name and title, the nature of the permitted competitive activity, and confirms unanimous board approval. There are no financial statements, no mention of financial results, no regulatory certifications, or report attachments. The content is about a board/management decision related to managerial permissions and conflicts of interest, which fits the category of Board/Management Information (MANG). The document is not a full report, nor an announcement of a report publication, nor a certification. Therefore, the best classification is MANG with high confidence.
2022-08-02 Chinese
公告董事會通過111年第二季合併財務報告
Interim / Quarterly Report Classification · 95% confidence The document is a public announcement from a listed company (1720 生達) reporting the board's approval of the consolidated financial report for the second quarter of the year 111 (Taiwan calendar, equivalent to 2022). It includes cumulative financial figures for the period 111/01/01 to 111/06/30, such as revenue, gross profit, operating profit, net profit before tax, net profit, net profit attributable to parent company owners, earnings per share, total assets, total liabilities, and equity attributable to parent company owners. The document is concise (909 characters) and contains substantive financial data for a period shorter than a full fiscal year (half-year). This matches the definition of an Interim / Quarterly Report (IR). It is not merely an announcement of a report publication but contains actual financial data and analysis for the interim period. Therefore, the correct classification is IR with high confidence.
2022-08-02 Chinese
111年06月內部人持股異動(事後)
Director's Dealing Classification · 100% confidence The document contains detailed tables listing shareholdings of insiders, including directors, managers, and their related parties. It shows the number of shares held, changes in holdings, and classifications of shares for various insiders. This type of document is typical of a Director's Dealing report, which discloses personal share transactions by company directors and executives. There is no indication of financial statements, earnings data, or meeting materials. The document is not an announcement of a report but a detailed disclosure of insider shareholdings and transactions. Therefore, the appropriate classification is Director's Dealing (DIRS).
2022-07-13 Chinese
111年06月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed disclosure of shareholdings and pledged shares by insiders and related parties of the company 生達化學製藥股份有限公司. It lists shareholdings by directors, supervisors, and senior management, including pledged shares and shares held by spouses or minors. The document is focused on insider shareholdings and does not contain financial statements, earnings data, or management discussion. It is not an announcement of a report but a direct disclosure of insider shareholdings. This matches the definition of Director's Dealing (DIRS), which covers reports of personal share transactions or holdings by company directors and executives. The document length is 2437 characters, which is consistent with a detailed insider shareholding report rather than a full financial report or announcement. Therefore, the appropriate classification is DIRS with high confidence.
2022-07-13 Chinese
公告本公司董事會決議現金股利配息基準日
Notice of Dividend Amount Classification · 95% confidence The document is a short announcement from a company regarding the board resolution on the cash dividend distribution date, including details such as dividend amount, ex-dividend date, record date, and payment date. It does not contain financial statements or detailed financial analysis but is an official notice about dividend payment details. According to the filing definitions, announcements about dividend amounts and payment dates fall under 'Notice of Dividend Amount (DIV)'. The document length is short (845 characters), consistent with a dividend notice rather than a full report. Therefore, the correct classification is DIV with high confidence.
2022-07-12 Chinese
111年年報及股東會資料 — 2022_1720_20220621F17.pdf
Regulatory Filings
2022-07-08 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.